4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report released on Thursday,Weiss Ratings reports.

FDMT has been the subject of a number of other reports. The Goldman Sachs Group lowered their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Roth Capital lowered their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday. Barclays lowered their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. Finally, Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of 4D Molecular Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $30.40.

4D Molecular Therapeutics Trading Up 6.4%

Shares of FDMT stock opened at $7.10 on Thursday. The business’s 50-day moving average price is $4.62 and its 200-day moving average price is $4.13. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $17.41. The firm has a market capitalization of $331.57 million, a price-to-earnings ratio of -2.01 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. On average, sell-side analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of 4D Molecular Therapeutics during the fourth quarter valued at approximately $50,000. Velan Capital Investment Management LP purchased a new stake in 4D Molecular Therapeutics in the 4th quarter valued at $56,000. Virtus ETF Advisers LLC raised its position in 4D Molecular Therapeutics by 173.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company’s stock valued at $58,000 after buying an additional 6,560 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $42,000. Finally, Los Angeles Capital Management LLC bought a new position in 4D Molecular Therapeutics in the 2nd quarter valued at $42,000. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.